(1994). Bihain BE: Identification of a lipolysisstimulated receptor that is distinct from the LDL receptor and the LDL receptor-related protein. Biochemistry
(1997). Bihain BE: Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
(1995). Bihain BE: Mechanism of activation and functional significance of the lipolysis-stimulated receptor. Evidence for a role as chylomicron remnant receptor. Biochemistry
(2006). Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
(2001). Dey SK: Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation.
(2004). Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR-/- embryos at 12.5 to 14.5 days of gestation.
(1995). ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res
(2005). FM: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res
(1992). FT: Free fatty acids activate a high-affinity saturable pathway for degradation of low-density lipoproteins in fibroblasts from a subject homozygous for familial hypercholesterolemia. Biochemistry
(1995). FT: Inhibitory effect on the lipolysis-stimulated receptor of the 39-kDa receptor-associated protein.
(1998). FT: The lipolysis stimulated receptor: a gene at last. Curr Opin Lipidol
(2005). Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res
(2001). Givol D: DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene
(2001). GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.
(2004). Irizarry RA: Preprocessing of oligonucleotide array data. Nat Biotechnol
(2001). Koeffler HP: Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
(2006). MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis
(1999). Molecular cloning of a lipolysis-stimulated remnant receptor expressed in the liver.
(2005). Orntoft TF: A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res
(2005). Orntoft TF: Gene expression profiling of noninvasive primary urothelial tumours using microarrays.
(2001). Orntoft TF: Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Research
(2003). Orntoft TF: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet
(2005). Orntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology
(2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res